Caenorhabditis elegans as a model under hyperglicemic conditions to evaluate insulin-loaded nanoparticles

• Martínez López AL ^[1] ; Carlos J. González Navarro ^[2] ; J.L. Vizmanos ^[3] ; Juan Manuel Irache Garreta ^[3]
  1. [1] Department of Chemistry and Pharmaceutical Technology, University of Navarra, Pamplona 31080, Spain
  2. [2] Center for Nutrition Research, University of Navarra, Pamplona 31080, Spain
  3. [3] Department of Biochemistry & Genetics, University of Navarra, Pamplona 31080, Spain.

  Mostrar afiliaciones +
• Localización: RESCIFAR Revista Española de Ciencias Farmacéuticas, ISSN-e 2660-6356, Vol. 2, Nº. 2, 2021 (Ejemplar dedicado a: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA), págs. 202-204
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • The oral bioavailability of peptides therapeutics (e.g. insulin) is hampered by both the harsh gastrointestinal environment and poorly penetrating of biological barriers such as mucus layer. In order to solvent these issues and thus enhance the oral absorption of these macromolecules, one possible strategy may be their encapsulation into polymeric nanoparticles with mucus-penetrating properties. In this context, the aim of this work was to explore the potential of mucus-permeating nanoparticles based on the coating of zein nanoparticles (NP) with a polymer conjugate containing PEG (PPA), as carriers for the oral delivery of insulin. For this purpose, the resulting nanoparticles were characterized and their biodistribution and efficacy evaluated in rats and Caenorhabditis elegans (C. elegans), respectively.